Immunoregulation in cancer, chronic inflammatory and...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007230, C435S007240, C435S007920

Reexamination Certificate

active

07960126

ABSTRACT:
The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.

REFERENCES:
patent: 5284750 (1994-02-01), Silvestrini et al.
patent: 6737057 (2004-05-01), Zaghouani
patent: 2003/0021792 (2003-01-01), Roben et al.
patent: WO 91/09619 (1991-07-01), None
patent: WO 02/30465 (2002-04-01), None
patent: WO 03/099312 (2003-12-01), None
patent: WO 2006/043891 (2006-04-01), None
patent: WO 2006/110091 (2006-10-01), None
patent: WO 2008/136736 (2008-11-01), None
Anderson, Donald C. et al., “Contributions of the Mac-1 Glycoprotein Family to Adherence-Dependent Granulocyte Functions: Structure-Function Assessments Employing Subunit-Specific Monoclonal Antibodies” The Journal of Immunology, Jul. 1, 1986, pp. 15-27, vol. 137, No. 1.
Cioli, Valerio et al., “A New Protein Antidenaturant Agent, Bindarit, Reduces Secondary Phase of Adjuvant Arthritis in Rats” Journal of Rheumatology, 1992, pp. 1735-1742, vol. 19, No. 11.
Davis, George E., “The Mac-1 and p150,95 β2Integrins Bind Denatured Proteins to Mediate Leukocyte Cell-Substrate Adhesion” Experimental Cell Research, 1992, pp. 242-252, vol. 200.
Davis, George E. et al., “The α4β1integrin can mediate leukocyte adhesion to casein and denatured protein substrates” Journal of Leukocyte Biology, 1997, pp. 318-328, vol. 62.
Håkansson, A. et al., “Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment” British Journal of Cancer, 1996, pp. 670-676, vol. 74.
Håkansson, A. et al., “Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes” British Journal of Cancer, 2001, pp. 1871-1877, vol. 85, No. 12.
Saso, Luciano et al., “Inhibition of Protein Denaturation by Fatty Acids, Bile Salts and Other Natural Substances: A New Hypothesis for the Mechanism of Action of Fish Oil in Rheumatic Diseases” Jpn. J. Pharmacol., 1999, pp. 89-99, vol. 79.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Immunoregulation in cancer, chronic inflammatory and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoregulation in cancer, chronic inflammatory and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoregulation in cancer, chronic inflammatory and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2703414

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.